feed,title,long_url,short_url
Benzinga,Turning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR Symposium,https://www.benzinga.com/pressreleases/20/10/g18044266/turning-point-therapeutics-presents-initial-clinical-data-from-phase-1-shield-1-study-of-novel-met,https://j.mp/2ToAcj8
